<p>Ionis 制药（NASDAQ:IONS - 获取免费报告）在周二发布的研究报告中，目标价格被美国银行从 86.00 美元上调至 97.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。美国银行的目标价格暗示该股票当前价格有 21.93% 的潜在上涨空间。</p>
<p>获取 <strong>Ionis 制药</strong> 的提醒：</p>
<ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
<p>其他一些研究公司也最近对 IONS 发表了看法。富国银行将 Ionis 制药的目标价格从 77.00 美元上调至 82.00 美元，并在 8 月 22 日的研究报告中给予该公司 “增持” 评级。派珀·桑德勒将 Ionis 制药的目标价格从 70.00 美元上调至 77.00 美元，并在 11 月 4 日的研究报告中给予该股票 “增持” 评级。雷蒙德·詹姆斯金融在 10 月 30 日的报告中重申了 “强烈买入” 评级，并将 Ionis 制药的目标价格设定为 89.00 美元（上调自 85.00 美元）。Needham &amp; Company LLC 在 10 月 30 日的研究报告中将 Ionis 制药的目标价格从 78.00 美元上调至 90.00 美元，并给予该股票 “买入” 评级。最后，斯蒂费尔·尼古拉斯在 10 月 6 日的研究报告中将 Ionis 制药的目标价格从 43.00 美元上调至 67.00 美元，并给予该公司 “持有” 评级。一位分析师对该股票给予了强烈买入评级，十七位分析师给予买入评级，三位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 84.85 美元。</p>
<p><strong>查看我们最新的 IONS 股票分析</strong></p>
<h2>Ionis 制药股价下跌 2.4%</h2>
<p>在周二的交易时段，NASDAQ IONS 股价下跌 1.96 美元，跌至 79.56 美元。该公司交易了 856,364 股，低于其平均交易量 2,067,020 股。该股票的 50 日移动平均价格为 73.94 美元，200 日移动平均价格为 55.04 美元。该公司的速动比率为 2.78，流动比率为 2.79，债务与股本比率为 0.96。Ionis 制药的 52 周最低价为 23.95 美元，52 周最高价为 83.61 美元。该股票的市值为 128.9 亿美元，市盈率为-47.07，贝塔值为 0.29。</p>
<p>Ionis 制药（NASDAQ:IONS - 获取免费报告）在 10 月 29 日星期三发布了季度财报。该公司报告每股收益（EPS）为-0.80 美元，超出市场共识预期的-1.15 美元，超出幅度为 0.35 美元。该季度的营业收入为 1.5672 亿美元，而分析师预期为 1.3175 亿美元。Ionis 制药的股本回报率为-44.26%，净利润率为-26.45%。该公司的季度收入同比增长 17.2%。去年同期，该公司每股收益为-0.95 美元。分析师预测 Ionis 制药在本财年的每股收益将为-3.5 美元。</p>
<h2>Ionis 制药的内部交易</h2>
<p>在其他新闻中，执行副总裁 Brian Birchler 在 11 月 6 日的交易中出售了 8,000 股该公司的股票。股票以平均 76.17 美元的价格出售，总价值为 609,360.00 美元。出售完成后，该执行副总裁持有该公司 48,826 股，价值约为 3,719,076.42 美元。此次交易使其持股减少了 14.08%。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。此外，执行副总裁 Shannon L. Devers 在 11 月 25 日的交易中出售了 16,777 股该股票。股票以平均 80.91 美元的价格出售，总交易额为 1,357,427.07 美元。交易完成后，该执行副总裁持有该公司 17,494 股，价值约为 1,415,439.54 美元。这代表其持股减少了 48.95%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售 506,566 股公司股票，价值为 35,854,552 美元。内部人士持有公司股票的比例为 2.71%。</p>
<h2>Ionis 制药的机构交易</h2>
<p>对该股票的对冲基金最近进行了买入和卖出交易。Steigerwald Gordon &amp; Koch Inc.在第三季度购买了 Ionis 制药的新头寸，价值 25,000 美元。Golden State Wealth Management LLC 在第三季度将其在 Ionis 制药的持股增加了 198.4%。Golden State Wealth Management LLC 现在拥有 376 股该公司的股票，价值 25,000 美元，此前在上个季度又购买了 250 股。Mather Group LLC 在第三季度购买了 Ionis 制药的新头寸，价值约 27,000 美元。Allworth Financial LP 在第二季度将其在 Ionis 制药的持股增加了 231.8%。Allworth Financial LP 现在拥有 740 股该公司的股票，价值 29,000 美元，此前在上个季度又购买了 517 股。最后，Quarry LP 在第三季度购买了 Ionis 制药的新股份，价值约 38,000 美元。对冲基金和其他机构投资者持有公司 93.86% 的股票。</p>
<h2>Ionis 制药公司简介</h2>
<p>（获取免费报告）</p>
<p>Ionis 制药公司在美国发现和开发 RNA 靶向治疗药物。该公司提供 SPINRAZA 用于治疗儿童和成人的脊髓性肌萎缩症（SMA）；TEGSEDI，一种用于治疗成人遗传性转甲状腺素淀粉样变性引起的多发性神经病的抗病毒注射剂；以及 WAYLIVRA，一种用于治疗家族性乳糜微粒血症（FCS）和家族性部分脂肪萎缩症的抗病毒药物。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非 Ionis 制药</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>UiPath 因财报大涨：投资者应该追逐这一势头吗？</li>
<li>什么是股息冠军？如何投资于这些冠军</li>
<li>Pure Storage 下跌 27%：真正的机会还是应得的修正？</li>
<li>3 只前景良好的金融科技股票</li>
<li>到 2026 年油价可能跌至 55 美元——对这个能源 ETF 来说是坏消息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Ionis 制药吗？</h2>
<p>在考虑 Ionis 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Ionis 制药并不在名单上。</p>
<p>虽然 Ionis 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ionis制药

<p>美国银行将 Ionis 制药的目标股价从 86 美元上调至 97 美元，维持 “买入” 评级，暗示潜在上涨幅度为 21.93%。其他公司也调整了他们的目标，市场共识为 84.85 美元。Ionis 的股票下跌了 2.4%，报 79.56 美元。最近的财报超出预期，收入同比增长 17.2%。内部交易包括大量股票出售。对冲基金正在积极交易 Ionis 的股票</p>

<p>Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) had its target price increased by Bank of America from $86.00 to $97.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. Bank of America's target price would suggest a potential upside of 21.93% from the stock's current price.</p>
<div class="lb-trans"><p>Ionis 制药（NASDAQ:IONS - 获取免费报告）在周二发布的研究报告中，目标价格被美国银行从 86.00 美元上调至 97.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。美国银行的目标价格暗示该股票当前价格有 21.93% 的潜在上涨空间。</p>
</div><p>Get <strong>Ionis Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ionis 制药</strong> 的提醒：</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
</div><p>A number of other research firms have also recently weighed in on IONS. Wells Fargo &amp; Company boosted their price objective on shares of Ionis Pharmaceuticals from $77.00 to $82.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, August 22nd. Piper Sandler lifted their price target on shares of Ionis Pharmaceuticals from $70.00 to $77.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, November 4th. Raymond James Financial reiterated a &#34;strong-buy&#34; rating and set a $89.00 price target (up from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. Needham &amp; Company LLC raised their price objective on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 30th. Finally, Stifel Nicolaus boosted their target price on Ionis Pharmaceuticals from $43.00 to $67.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $84.85.</p>
<div class="lb-trans"><p>其他一些研究公司也最近对 IONS 发表了看法。富国银行将 Ionis 制药的目标价格从 77.00 美元上调至 82.00 美元，并在 8 月 22 日的研究报告中给予该公司 “增持” 评级。派珀·桑德勒将 Ionis 制药的目标价格从 70.00 美元上调至 77.00 美元，并在 11 月 4 日的研究报告中给予该股票 “增持” 评级。雷蒙德·詹姆斯金融在 10 月 30 日的报告中重申了 “强烈买入” 评级，并将 Ionis 制药的目标价格设定为 89.00 美元（上调自 85.00 美元）。Needham &amp; Company LLC 在 10 月 30 日的研究报告中将 Ionis 制药的目标价格从 78.00 美元上调至 90.00 美元，并给予该股票 “买入” 评级。最后，斯蒂费尔·尼古拉斯在 10 月 6 日的研究报告中将 Ionis 制药的目标价格从 43.00 美元上调至 67.00 美元，并给予该公司 “持有” 评级。一位分析师对该股票给予了强烈买入评级，十七位分析师给予买入评级，三位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 84.85 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on IONS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 IONS 股票分析</strong></p>
</div><h2>Ionis Pharmaceuticals Trading Down 2.4%</h2>
<div class="lb-trans"><h2>Ionis 制药股价下跌 2.4%</h2>
</div><p>NASDAQ IONS traded down $1.96 during trading hours on Tuesday, hitting $79.56. 856,364 shares of the company were exchanged, compared to its average volume of 2,067,020. The stock has a 50-day moving average price of $73.94 and a 200 day moving average price of $55.04. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $83.61. The stock has a market cap of $12.89 billion, a PE ratio of -47.07 and a beta of 0.29.</p>
<div class="lb-trans"><p>在周二的交易时段，NASDAQ IONS 股价下跌 1.96 美元，跌至 79.56 美元。该公司交易了 856,364 股，低于其平均交易量 2,067,020 股。该股票的 50 日移动平均价格为 73.94 美元，200 日移动平均价格为 55.04 美元。该公司的速动比率为 2.78，流动比率为 2.79，债务与股本比率为 0.96。Ionis 制药的 52 周最低价为 23.95 美元，52 周最高价为 83.61 美元。该股票的市值为 128.9 亿美元，市盈率为-47.07，贝塔值为 0.29。</p>
</div><p>Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.35. The business had revenue of $156.72 million during the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the company earned ($0.95) EPS. Analysts forecast that Ionis Pharmaceuticals will post -3.5 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Ionis 制药（NASDAQ:IONS - 获取免费报告）在 10 月 29 日星期三发布了季度财报。该公司报告每股收益（EPS）为-0.80 美元，超出市场共识预期的-1.15 美元，超出幅度为 0.35 美元。该季度的营业收入为 1.5672 亿美元，而分析师预期为 1.3175 亿美元。Ionis 制药的股本回报率为-44.26%，净利润率为-26.45%。该公司的季度收入同比增长 17.2%。去年同期，该公司每股收益为-0.95 美元。分析师预测 Ionis 制药在本财年的每股收益将为-3.5 美元。</p>
</div><h2>Insider Transactions at Ionis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ionis 制药的内部交易</h2>
</div><p>In other news, EVP Brian Birchler sold 8,000 shares of the business's stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $76.17, for a total value of $609,360.00. Following the completion of the sale, the executive vice president owned 48,826 shares in the company, valued at approximately $3,719,076.42. The trade was a 14.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon L. Devers sold 16,777 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $80.91, for a total transaction of $1,357,427.07. Following the transaction, the executive vice president owned 17,494 shares in the company, valued at approximately $1,415,439.54. This represents a 48.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 506,566 shares of company stock valued at $35,854,552. Insiders own 2.71% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Brian Birchler 在 11 月 6 日的交易中出售了 8,000 股该公司的股票。股票以平均 76.17 美元的价格出售，总价值为 609,360.00 美元。出售完成后，该执行副总裁持有该公司 48,826 股，价值约为 3,719,076.42 美元。此次交易使其持股减少了 14.08%。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。此外，执行副总裁 Shannon L. Devers 在 11 月 25 日的交易中出售了 16,777 股该股票。股票以平均 80.91 美元的价格出售，总交易额为 1,357,427.07 美元。交易完成后，该执行副总裁持有该公司 17,494 股，价值约为 1,415,439.54 美元。这代表其持股减少了 48.95%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售 506,566 股公司股票，价值为 35,854,552 美元。内部人士持有公司股票的比例为 2.71%。</p>
</div><h2>Institutional Trading of Ionis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ionis 制药的机构交易</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Steigerwald Gordon &amp; Koch Inc. purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $25,000. Golden State Wealth Management LLC grew its stake in Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company's stock valued at $25,000 after purchasing an additional 250 shares during the last quarter. Mather Group LLC. purchased a new position in Ionis Pharmaceuticals in the third quarter valued at about $27,000. Allworth Financial LP raised its holdings in Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company's stock worth $29,000 after purchasing an additional 517 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at about $38,000. Hedge funds and other institutional investors own 93.86% of the company's stock.</p>
<div class="lb-trans"><p>对该股票的对冲基金最近进行了买入和卖出交易。Steigerwald Gordon &amp; Koch Inc.在第三季度购买了 Ionis 制药的新头寸，价值 25,000 美元。Golden State Wealth Management LLC 在第三季度将其在 Ionis 制药的持股增加了 198.4%。Golden State Wealth Management LLC 现在拥有 376 股该公司的股票，价值 25,000 美元，此前在上个季度又购买了 250 股。Mather Group LLC 在第三季度购买了 Ionis 制药的新头寸，价值约 27,000 美元。Allworth Financial LP 在第二季度将其在 Ionis 制药的持股增加了 231.8%。Allworth Financial LP 现在拥有 740 股该公司的股票，价值 29,000 美元，此前在上个季度又购买了 517 股。最后，Quarry LP 在第三季度购买了 Ionis 制药的新股份，价值约 38,000 美元。对冲基金和其他机构投资者持有公司 93.86% 的股票。</p>
</div><h2>Ionis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Ionis 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.</p>
<div class="lb-trans"><p>Ionis 制药公司在美国发现和开发 RNA 靶向治疗药物。该公司提供 SPINRAZA 用于治疗儿童和成人的脊髓性肌萎缩症（SMA）；TEGSEDI，一种用于治疗成人遗传性转甲状腺素淀粉样变性引起的多发性神经病的抗病毒注射剂；以及 WAYLIVRA，一种用于治疗家族性乳糜微粒血症（FCS）和家族性部分脂肪萎缩症的抗病毒药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Ionis Pharmaceuticals</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>UiPath Surges on Earnings: Should Investors Chase the Momentum?</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Pure Storage's 27% Fall: Real Opportunity or Deserved Correction?</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Oil Prices May Fall to $55 by 2026—Bad News for This Energy ETF</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Ionis 制药</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>UiPath 因财报大涨：投资者应该追逐这一势头吗？</li>
<li>什么是股息冠军？如何投资于这些冠军</li>
<li>Pure Storage 下跌 27%：真正的机会还是应得的修正？</li>
<li>3 只前景良好的金融科技股票</li>
<li>到 2026 年油价可能跌至 55 美元——对这个能源 ETF 来说是坏消息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=IONS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Ionis 制药吗？</h2>
</div><p>Before you consider Ionis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ionis 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Ionis 制药并不在名单上。</p>
</div><p>While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ionis 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ionis 制药（NASDAQ:IONS）的目标股价被上调至 97.00 美元